Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 3589-3589 ◽  
Author(s):  
Francis Levi ◽  
Michel Ducreux ◽  
Denis Michel Smith ◽  
Mohamed Hebbar ◽  
Céline Lepère ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Hepatic Artery ◽  
Liver Surgery ◽  
Hepatic Artery Infusion ◽  
Unresectable Liver Metastases ◽  
Previously Treated ◽  
European Trial

scholarly journals Conversion to Resectability Using Hepatic Artery Infusion Plus Systemic Chemotherapy for the Treatment of Unresectable Liver Metastases From Colorectal Carcinoma

2009 ◽  
Vol 27 (21) ◽  
pp. 3465-3471 ◽  
Author(s):  
Nancy E. Kemeny ◽  
Fidel D. Huitzil Melendez ◽  
Marinela Capanu ◽  
Philip B. Paty ◽  
Yuman Fong ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Systemic Chemotherapy ◽  
Hepatic Metastases ◽  
Hepatic Arterial Infusion ◽  
Hepatic Artery Infusion ◽  
Baseline Variable ◽  
Unresectable Liver Metastases ◽  
Previously Treated ◽  
Additional Value

Purpose To determine the conversion to resectability in patients with unresectable liver metastases from colorectal cancer treated with hepatic arterial infusion (HAI) plus systemic oxaliplatin and irinotecan (CPT-11). Patients and Methods Forty-nine patients with unresectable liver metastases (53% previously treated with chemotherapy) were enrolled onto a phase I protocol with HAI floxuridine and dexamethasone plus systemic chemotherapy with oxaliplatin and irinotecan. Results Ninety-two percent of the 49 patients had complete (8%) or partial (84%) response, and 23 (47%) of the 49 patients were able to undergo resection in a group of patients with extensive disease (73% with > five liver lesions, 98% with bilobar disease, 86% with ≥ six segments involved). For chemotherapy-naïve and previously treated patients, the median survival from the start of HAI therapy was 50.8 and 35 months, respectively. The only baseline variable significantly associated with a higher resection rate was female sex. Variables reflecting extensive anatomic disease, such as number of lesions or number of vessels involved, were not significantly associated with the probability of resection. Conclusion The combination of regional HAI floxuridine/dexamethasone and systemic oxaliplatin and irinotecan is an effective regimen for the treatment of patients with unresectable liver metastases from colorectal cancer, demonstrating a 47% conversion to resection (57% in chemotherapy-naïve patients). Future randomized trials should compare HAI plus systemic chemotherapy with systemic therapy alone to assess the additional value of HAI therapy in converting patients with hepatic metastases to resectability.

Sign in / Sign up

Export Citation Format

Share Document